NASDAQ$BNTX
BioNTech SE-ADR · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
BioNTech reported a decline in Q4 2024 revenue due to lower COVID-19 vaccine demand, but maintained a strong financial position with significant oncology pipeline advancements.
BioNTech's Q4 2024 revenue declined to €1.19 billion from €1.48 billion in Q4 2023, primarily due to reduced COVID-19 vaccine demand. Net profit also decreased to €259.5 million from €457.9 million in the prior year quarter. The company continues to advance its oncology pipeline, with multiple Phase 3 trials initiated. Cash and cash equivalents, including investments, remained strong at €17.4 billion.
- Q4 2024 revenue decreased 19.5% year-over-year to €1.19 billion.
- Net profit declined to €259.5 million from €457.9 million in Q4 2023.
- R&D expenses increased due to ongoing oncology pipeline investments.
- Cash and cash equivalents stood at €9.76 billion, ensuring strong liquidity.
Headline financials
Revenue & EPS history
BioNTech SE · Revenue · Quarterly
$1.24B
Forward guidance
BioNTech expects 2025 revenue between €1.7 billion and €2.2 billion, driven by continued COVID-19 vaccine demand, pandemic preparedness contracts, and oncology developments.
Tailwinds
- Expected 2025 revenue between €1.7 billion and €2.2 billion.
- Continued investment in oncology with multiple Phase 3 trials initiated.
- Strong liquidity position with €17.4 billion in cash and securities.
- Strategic acquisitions to enhance R&D capabilities.
- Expansion of mRNA vaccine pipeline beyond COVID-19.
Headwinds
- COVID-19 vaccine demand remains uncertain.
- Ongoing legal disputes may impact financial performance.
- Significant increase in R&D expenses may weigh on profitability.
- Potential negative revenue impact from Pfizer’s inventory write-downs.
- Company does not expect to report a positive net income in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+5.7%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+13.8%
Q4 2020
Best reaction
-14.6%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2025 | -3.7% | -5.3% | -9.9% | |
| Q2 2025 | +2.5% | +4.0% | -6.4% | |
| Q4 2024 | -3.2% | -8.6% | -13.5% | |
| Q3 2024 | -0.5% | -0.8% | +2.9% | |
| Q1 2024 | -2.0% | -1.1% | +10.5% | |
| Q4 2023 | -2.3% | -1.2% | -7.8% | |
| Q3 2023 | +6.9% | +3.9% | +5.8% | |
| Q2 2023 | -4.4% | +0.4% | +12.8% | |
| Q1 2023 | -3.5% | -2.9% | +0.9% | |
| Q4 2022 | -4.1% | -2.8% | -13.7% | |
| Q3 2022 | +4.3% | +0.1% | +5.4% | |
| Q2 2022 | -14.1% | -12.4% | -21.3% | |
| Q4 2021 | -1.1% | +16.6% | +18.8% | |
| Q1 2022 | +6.1% | +16.6% | +18.8% | |
| Q3 2021 | -3.0% | -1.8% | +17.2% | |
| Q2 2021 | +7.1% | -3.0% | -13.6% | |
| Q1 2021 | +7.8% | +4.9% | +31.5% | |
| Q4 2020 | +13.8% | +10.8% | +38.9% | |
| Q3 2020 | +4.4% | +1.1% | +23.6% | |
| Q2 2020 | -6.5% | -7.2% | -17.2% | |
| Q1 2020 | -3.0% | -1.0% | -2.8% | |
| Q4 2019 | -14.6% | -14.9% | -23.4% | |
| Q3 2019 | +3.7% | +9.6% | +74.9% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro